Ipilimumab clinical trials
Also written Yervoy, BMS-734016 and MDX-010.
ClinicalTrials.gov finds 993 studies for Ipilimumab. How that becomes 521 hereChecked on ClinicalTrials.gov
Every study that search finds has been read, apart from the 2 newest, to see whether and how it gives Ipilimumab. Its counts are asked again every night. How drug pages count
- 993Found by its intervention search · See all 993 hereIt also reads titles, arm labels, keywords and descriptions, and counts the drug’s other names. Of these, 862 name it in an intervention entry. The counts it shows beside each synonym overlap: a study writing two names counts under both.
- −25
Mention it without giving it — earlier treatment, a protocol code, a title naming another drug
- CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With SurgeryNCT00090896 · Not given here; tremelimumab is the CTLA-4 antibody givenReport a problem
- MSB0010445 and Stereotactic Body Radiation Therapy in Advanced MelanomaNCT01973608 · Earlier treatment, not given in this studyReport a problem
- Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030)NCT02083484 · Earlier treatment, not given in this studyReport a problem
- Cytokine Microdialysis for Real-Time Immune Monitoring in Glioblastoma Patients Undergoing Checkpoint BlockadeNCT03493932 · Earlier treatment, named only in eligibilityReport a problem
- CMP-001 in Combo With Nivolumab in Stage IIIB/C/D Melanoma Patients With Clinically Apparent Lymph Node DiseaseNCT03618641 · Earlier treatment, named only in eligibilityReport a problem
- Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced CancerNCT03860272 · Not given here; botensilimab is the CTLA-4 antibody givenReport a problem
- Study of Cabozantinib as 2nd Line Treatment in Subjects With Locally Advanced or Metastatic Renal Cell Carcinoma (RCC) With a Clear-Cell Component Who Progressed After 1st Line Treatment With Checkpoint InhibitorsNCT03945773 · Earlier treatment, not given in this studyReport a problem
- Anti-CD137 and Anti-CTLA-4 Monoclonal Antibody in Patients With Advanced CancerNCT04121676 · Not given here; botensilimab is the CTLA-4 antibody givenReport a problem
- CaboCHECK - Cabozantinib in Adult Patients With Advanced Renal Cell Carcinoma Following Prior Systemic Check Point Inhibition Therapy: a Retrospective, Non-interventional StudyNCT04147143 · Earlier treatment, not given in this studyReport a problem
- Pembrolizumab + Capecitabine/Oxaliplatin (CapeOx) -HER2 Nagative and Pembrolizumab + Trastuzumab + Cisplatin/Capecitabine HER2 PositiveNCT04249739 · Earlier treatment, named only in eligibilityReport a problem
- Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II MelanomaNCT04274816 · Not given here; tremelimumab is the CTLA-4 antibody givenReport a problem
- Study of TLR9 Agonist Vidutolimod (CMP-001) in Combination With Nivolumab vs. NivolumabNCT04401995 · Earlier treatment, named only in eligibilityReport a problem
- JSI-1187-01 Monotherapy and in Combination With Dabrafenib for Advanced Solid Tumors With MAPK Pathway MutationsNCT04418167 · Earlier treatment, named only in eligibilityReport a problem
- AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable AngiosarcomaNCT04607200 · Not given here; zalifrelimab is the CTLA-4 antibody givenReport a problem
- Cabozantinib as Subsequent Therapy to an Immune Checkpoint Based Therapy in Renal Cell CarcinomaNCT04714697 · Earlier treatment, not given in this studyReport a problem
- Intra-tumor Injection of Drug-eluting Microspheres With Multiple DrugsNCT04770207 · Not named; a CTLA-4 antibody of any kind in beadsReport a problem
- rHSC-DIPGVax Plus Checkpoint Blockade for the Treatment of Newly Diagnosed DIPG and DMGNCT04943848 · Not given here; zalifrelimab is the CTLA-4 antibody givenReport a problem
- Axitinib Intensification Plus Nivolumab or Nivolumab Alone After Nivolumab Plus Ipilimumab in mRCC PatientsNCT05817903 · Earlier induction, not given in this studyReport a problem
- Omitting Therapeutic Lymph Node Dissection in Patients With Melanoma (Stage 3) and Major Pathological Response in the Index Lymph NodeNCT06754904 · Earlier treatment; omitting surgery is studiedReport a problem
- Primary Tumor Ablation and Outcome in Metastatic Renal Cell Carcinoma Treated With Immunotherapy Combinations.NCT06903312 · Earlier induction; tumour ablation is studiedReport a problem
- QL1706-SOX vs SOX Alone as Neoadjuvant Therapy for Resectable Diffuse-Type Gastric CancerNCT07315035 · Named only in comparison; QL1706 is givenReport a problem
- Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy and Sequential Thoracic Radiotherapy for Extensive-Stage Small Cell Lung CancerNCT07349225 · A slip in the record; iparomlimab and tuvonralimab are givenReport a problem
- A Clinical Study Evaluating the Safety, Tolerability, and Effect on HIV Reservoir of Ibalizumab Combined With Chidamide (a Histone Deacetylase Inhibitor) in People Living With HIVNCT07635992 · Not given; a mistranslation of iparomlimab and tuvonralimabReport a problem
- An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUCNCT07720284 · Named only in a drug descriptionReport a problem
- Neoadjuvant Iparomlimab and Tuvonralimab With Nab-P-SOX in Locally Advanced Gastric or Gastroesophageal Junction CancerNCT07867392 · Named only in comparison; QL1706 is givenReport a problem
- −1New since the last reading, not read yet
- +1Give it under a name that search misses: a biosimilar’s code or a misspelling
- 968Give Ipilimumab to participants
- −99Observe patients on it, or give it outside a trial
- −6Use it as a tool: an imaging tracer or a test of drug response
- −27Compare another treatment with it
- −315Give it beside what is tested
- 521Test it: the count on this site
Get an email when these change. Save the Ipilimumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- 25 Mar 2011 · YERVOY · BLA 125377 (FDA, Drugs@FDA)
- European Union
- 13 Jul 2011 · Yervoy · EMEA/H/C/002213 (EMA)
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Name
Brand
- Yervoy
- 214
In one entry with another drug
Given together, or one or the other
Biosimilars
- CS1002
- 2
Studies by the year they started
520 studies that test it; most in 2017 (61); 1 more planned to start later
| Year | Studies |
|---|---|
| 2001 | 2 |
| 2002 | 5 |
| 2003 | 7 |
| 2004 | 6 |
| 2005 | 5 |
| 2006 | 6 |
| 2007 | 2 |
| 2008 | 3 |
| 2009 | 9 |
| 2010 | 8 |
| 2011 | 14 |
| 2012 | 29 |
| 2013 | 23 |
| 2014 | 20 |
| 2015 | 24 |
| 2016 | 40 |
| 2017 | 61 |
| 2018 | 50 |
| 2019 | 53 |
| 2020 | 31 |
| 2021 | 29 |
| 2022 | 23 |
| 2023 | 10 |
| 2024 | 15 |
| 2025 | 11 |
| 2026 | 34 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 96 · Other 425
Bristol-Myers Squibb (86) · National Cancer Institute (NCI) (48) · M.D. Anderson Cancer Center (29) · Memorial Sloan Kettering Cancer Center (15) · The Netherlands Cancer Institute (15) · Dana-Farber Cancer Institute (12) · H. Lee Moffitt Cancer Center and Research Institute (11) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (9)
Often tested with
Tested in the same studies.
Nivolumab (320) · Cabozantinib (19) · Pembrolizumab (18) · Sintilimab (12) · Ipilimumab/Nivolumab Regimen (12) · Relatlimab (11) · Paclitaxel (10) · Cisplatin (9)
Related medicines
As reviewed, each with the page that says it.
Coming up
From the study records. Dates are the sponsors’ own estimates and often move.
Tested against it · 7 phase 3 studies under way
Ipilimumab is the comparator. A study of two new drugs counts under both.
- 1Pembrolizumab · National Cancer Institute (NCI)
- 1Volrustomig · AstraZeneca · next primary completion Nov 2028
- 1Darovasertib · IDEAYA Biosciences · next primary completion Jan 2027
- 1HLX13 · Shanghai Henlius Biotech · next primary completion Jun 2027
- 1Anzutresgene autoleucel · Immatics US, Inc. · next primary completion Jan 2028
- 1Sturlimogene erparepvec · Replimune, Inc. · next primary completion Jan 2030
New treatments tested with it · 8 most studied
New when their studies opened, with Ipilimumab beside them; studies of each.
Reaching primary completion within a year · 51, 1 in phase 3
Studies that test Ipilimumab, phase 3 first.
- Mar 2027A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerPhase 3 · Bristol-Myers Squibb
- Nov 2026Trial of Relatlimab, Nivolumab, and Ipilimumab in Patients With Asymptomatic and Symptomatic Melanoma Brain MetastasesPhase 2 · Stanford University
- Dec 2026Concurrent or Sequential Immunotherapy and Radiation Therapy in Patients With Metastatic Lung CancerPhase 1 · University of Chicago
- Dec 2026PHP and Immunotherapy in Metastasized UMPhase 1/2 · Leiden University Medical Center
- Dec 2026Testing the Addition of Immunotherapy Before Surgery for Patients With Sarcomatoid MesotheliomaPhase 2 · Alliance for Clinical Trials in Oncology
- Dec 2026Cabozantinib In Combo With NIVO + IPI In Advanced NCCRCCPhase 2 · Bradley A. McGregor, MD
- Dec 2026Surgical Nivolumab And Ipilimumab For Recurrent GBMPhase 1 · Gilbert Youssef
- Dec 2026Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric CancerPhase 2 · M.D. Anderson Cancer Center
- Dec 2026Nivolumab Combined With Ipilimumab for Patients With Advanced Rare Genitourinary TumorsPhase 2 · Dana-Farber Cancer Institute
- Dec 2026Nivolumab/Ipilimumab and Chemotherapy Combination in Advanced NSCLC Patients With HIV, HBV, HCV and Long Covid SyndromePhase 2 · Universita di Verona
Studies
Open first, then newest update. How each study uses Ipilimumab has had a first review, but it may not be perfect: check the study record before relying on it for anything important, and report a problem from its row. Some give it without naming it in an intervention entry: those were found by reading the record.
Testing it · 521
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With nivolumab and cabozantinib in rare cancersWritten as IpilimumabReport a problem
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05112601Added to nivolumab in dMMR endometrial cancerWritten as IpilimumabReport a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345With nivolumab in people with autoimmune disease, some armsWritten as IpilimumabReport a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingPhase 2The Netherlands Cancer InstituteNCT03815890Added to nivolumab before breast surgeryWritten as IpilimumabReport a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT06926790With nivolumab before lung cancer surgeryWritten as Nivolumab & IpilimumabReport a problem
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07919717With nivolumab before repeat surgery for recurrent liver cancerWritten as IpilimumabReport a problem
- A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung CancerNot yet recruitingPhase 2Tang-Du HospitalNCT07917767Ipilimumab N01 with a PD-1 antibody and chemotherapy before lung surgeryReport a problem
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingPhase 4IsalaNCT06031233Shorter infusion times studiedWritten as IpilimumabReport a problem
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingPhase 2Sun Yat-sen UniversityNCT07487662Ipilimumab N01 with sintilimab before liver cancer surgeryReport a problem
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingPhase 2Swiss Cancer InstituteNCT07574047Morning or afternoon infusions, one checkpoint optionReport a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767With nivolumab, cabozantinib and TACE in liver cancerWritten as IpilimumabReport a problem
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Ipilimumab N01 with sintilimab and bevacizumab in mesotheliomaReport a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879586Ipilimumab N01 added to sintilimab and chemoradiotherapyWritten as Ipilimumab & SintilimabReport a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879599Ipilimumab N01 added to sintilimab and chemoradiotherapyWritten as Ipilimumab & SintilimabReport a problem
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingPhase 2Fudan UniversityNCT07878221Ipilimumab N01 with sintilimab in MSI gastric cancerReport a problem
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839With nivolumab, sirolimus and prednisone in transplant recipientsWritten as IpilimumabReport a problem
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT06163820With nivolumab, bevacizumab and radiotherapy for brain metastasesWritten as IpilimumabReport a problem
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845With niraparib against FOLFIRI in pancreatic cancerWritten as IpilimumabReport a problem
- SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic CancerRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT07683221Ipilimumab N01 with sintilimab and chemotherapy after SBRTReport a problem
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991With fianlimab and cemiplimab in melanomaWritten as IpilimumabReport a problem
See all 521 studies that test Ipilimumab →
Behind its US label · 10 — the studies the FDA label of YERVOY describes
From the Clinical Studies section of YERVOY (2026-08), as openFDA has it. A study the site does not hold is left out.
- MDX-010 Antibody, MDX-1379 Melanoma Vaccine, or MDX-010/MDX-1379 Combination Treatment for Patients With Unresectable or Metastatic MelanomaCompletedPhase 3Bristol-Myers SquibbNCT00094653Report a problem
- Ipilimumab or High-Dose Interferon Alfa-2b in Treating Patients With High-Risk Stage III-IV Melanoma That Has Been Removed by SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT01274338Report a problem
- An Immuno-therapy Study to Evaluate the Effectiveness, Safety and Tolerability of Nivolumab or Nivolumab in Combination With Other Agents in Patients With Advanced Liver CancerCompletedPhase 1/2Bristol-Myers SquibbNCT01658878Report a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedPhase 3Bristol-Myers SquibbNCT01844505Report a problem
- Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)CompletedPhase 3Bristol-Myers SquibbNCT02231749Report a problem
- An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)CompletedPhase 3Bristol-Myers SquibbNCT02477826Report a problem
- Study of Nivolumab Combined With Ipilimumab Versus Pemetrexed and Cisplatin or Carboplatin as First Line Therapy in Unresectable Pleural Mesothelioma PatientsCompletedPhase 3Bristol-Myers SquibbNCT02899299Report a problem
- A Study to Evaluate Efficacy in Subjects With Esophageal Cancer Treated With Nivolumab and Ipilimumab or Nivolumab Combined With Fluorouracil Plus Cisplatin Versus Fluorouracil Plus CisplatinCompletedPhase 3Bristol-Myers SquibbNCT03143153Report a problem
- A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLCCompletedPhase 3Bristol-Myers SquibbNCT03215706Report a problem
- A Study of Nivolumab in Combination With Ipilimumab in Participants With Advanced Hepatocellular CarcinomaCompletedPhase 3Bristol-Myers SquibbNCT04039607Report a problem
Tested on its own · 67 — no other medicine in its arm
- Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate CancerActive, not recruitingPhase 1/2Memorial Sloan Kettering Cancer CenterNCT01688492Added to abiraterone and prednisone in prostate cancerWritten as IpilimumabReport a problem
- Ipilimumab for Head and Neck Cancer PatientsActive, not recruitingPhase 1Providence Health & ServicesNCT02812524Injected into the tumour in head and neck cancerWritten as Intratumoral IpilimumabReport a problem
- Neoadjuvant Lu-PSMA Radioligand Therapy and Ipilimumab in Men With Very High-risk Prostate CancerTerminatedPhase 1/2University Hospital, EssenNCT06388369Added to 177Lu-PSMA before prostate surgeryWritten as IpilimumabReport a problem
- Phase I Study of Ipilimumab Combined With Whole Brain Radiation Therapy or Radiosurgery for MelanomaCompletedPhase 1Sidney Kimmel Cancer Center at Thomas Jefferson UniversityNCT01703507Its dose with brain radiotherapy in melanomaWritten as IpilimumabReport a problem
- THE IPI - Trial in Advanced Melanoma: Melanoma Patients With Advanced DiseaseCompletedPhase 2Prof. Dr. med. Dirk SchadendorfNCT01355120Alone in advanced melanomaWritten as IpilimumabReport a problem
- T-Cell Responses to Neoantigens Post Treatment With Ipilimumab in Men With Metastatic Castration-Resistant Prostate CancerCompletedEarly Phase 1M.D. Anderson Cancer CenterNCT02113657Its effect on T cells in prostate cancerWritten as IpilimumabReport a problem
- Stereotactic Radiation Therapy and Ipilimumab in Treating Patients With Metastatic MelanomaCompletedPhase 2Ohio State University Comprehensive Cancer CenterNCT02107755With stereotactic radiotherapy in melanomaWritten as ipilimumabReport a problem
- A Trial of Neoadjuvant Therapy in Patients With Newly Diagnosed GlioblastomaTerminatedPhase 2University College, LondonNCT05074992Alone before glioblastoma surgeryWritten as IpilimumabReport a problem
- Ipilimumab and Local Radiation for Selected Solid TumorsTerminatedPhase 1Stanford UniversityNCT01769222Injected into the tumour with radiotherapyWritten as IpilimumabReport a problem
- A National Phase IV Study With Ipilimumab for Patients With Advanced Malignant Melanoma.Active, not recruitingPhase 4Oslo University HospitalNCT02068196Its use and safety across a national programmeWritten as IpilimumabReport a problem
- Study of Ipilimumab After Stem Cell Transplantation in People With Relapsed/Refractory Multiple MyelomaTerminatedPhase 1/2Memorial Sloan Kettering Cancer CenterNCT04635735Alone after stem cell transplant in myelomaWritten as IpilimumabReport a problem
- GEM STUDY: Radiation And Yervoy in Patients With Melanoma and Brain MetastasesCompletedPhase 2Grupo Español Multidisciplinar de MelanomaNCT02115139With radiotherapy for melanoma brain metastasesWritten as IpilimumabReport a problem
- Ipilimumab in Treating Patients With Metastatic or Recurrent Human Papilloma Virus-Related Cervical CancerCompletedPhase 2National Cancer Institute (NCI)NCT01693783Alone in HPV-related cervical cancerWritten as IpilimumabReport a problem
- A Study of Anti-CTLA-4 Antibody in Patients With Advanced Synovial SarcomaTerminatedPhase 2Ludwig Institute for Cancer ResearchNCT00140855Alone in synovial sarcomaWritten as ipilimumabReport a problem
- Ipilimumab Administered to Stage IIIC Stage IV Melanoma After Reg. T Cell Depletion With Denileukin DiftitoxTerminatedPhase 2University of LouisvilleNCT02009384After regulatory T cell depletion in melanomaWritten as IpilimumabReport a problem
- MDX-010 in Treating Patients With Stage IV Pancreatic Cancer That Cannot Be Removed By SurgeryCompletedPhase 2Bristol-Myers SquibbNCT00112580Alone in pancreatic cancerWritten as ipilimumabReport a problem
- RADVAX™: A STRATIFIED PHASE I/II DOSE ESCALATION TRIAL OF HYPOFRACTIONATED RADIOTHERAPY FOLLOWED BY IPILIMUMAB IN METASTATIC MELANOMACompletedPhase 1/2Abramson Cancer Center at Penn MedicineNCT01497808After radiotherapy, whose dose is escalated, in melanomaWritten as IpilimumabReport a problem
- Ipilimumab Induction in Patients With Melanoma Brain Metastases Receiving Stereotactic RadiosurgeryTerminatedPhase 2University of Michigan Rogel Cancer CenterNCT02097732Before radiosurgery for melanoma brain metastasesWritten as IpilimumabReport a problem
- A Phase I Study of CS1002 in Subjects With Advanced Solid TumorsCompletedPhase 1CStone PharmaceuticalsNCT04338724CS1002, a biosimilar, its dose escalated, aloneWritten as CS1002Report a problem
- Ipilimumab and Stereotactic Body Radiation Therapy (SBRT) in Advanced Solid TumorsCompletedPhase 1M.D. Anderson Cancer CenterNCT02239900Its dose with stereotactic radiotherapy in solid tumoursWritten as IpilimumabReport a problem
Showing 20 of 67. See all 67 →
Tested with established drugs · 41 — they are given beside it
- Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT05112601Added to nivolumab in dMMR endometrial cancerWritten as IpilimumabReport a problem
- A Study Assessing if it is Safe and Possible to Treat Brain Cancer Patients With Immunotherapy Before They Receive the Standard Treatment.RecruitingPhase 1University College, LondonNCT07134842Alone before standard treatment of glioblastomaWritten as Ipilimumab (3 mg/kg)Report a problem
- Ipilimumab With or Without High-Dose Recombinant Interferon Alfa-2b in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by SurgeryCompletedPhase 2National Cancer Institute (NCI)NCT01708941Two doses, with or without interferon, in melanomaWritten as IpilimumabReport a problem
- Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching BiomarkersActive, not recruitingPhase 3SWOG Cancer Research NetworkNCT02785952Added to nivolumab in squamous lung cancerWritten as IpilimumabReport a problem
- Association of Peripheral Blood Immunologic Response to Therapeutic Response to Adjuvant Treatment With Immune Checkpoint Inhibition (ICI) in Patients With Newly Diagnosed Glioblastoma or GliosarcomaCompletedPhase 2National Cancer Institute (NCI)NCT04817254Two doses with nivolumab and temozolomide in glioblastomaWritten as ipilimumab 3mg/kgReport a problem
- Anti-PD-1 Re-challenge After Immune Priming by Ipilimumab and Immune Boosting by Radiotherapy in Advanced NSCLCActive, not recruitingPhase 2The Netherlands Cancer InstituteNCT05401786To prime before cemiplimab rechallenge, with radiotherapyWritten as IpilimumabReport a problem
- Study Evaluating the Benefit of Adding Ipilimumab to the Combination of Atezolizumab and Bevacizumab in Patients With Hepatocellular Carcinoma Receiving First-line Systemic TherapyCompletedPhase 2/3Federation Francophone de Cancerologie DigestiveNCT05665348Added to atezolizumab and bevacizumab in liver cancerWritten as Ipilimumab InjectionReport a problem
- A Study of Nivolumab Combined With Ipilimumab Versus Nivolumab Alone in Participants With Advanced Kidney CancerActive, not recruitingPhase 3Bristol-Myers SquibbNCT03873402Added to nivolumab against placebo in kidney cancerWritten as IpilimumabReport a problem
- Low Dose Ipilimumab With Pembrolizumab in Treating Patients With Melanoma That Has Spread to the BrainCompletedPhase 2M.D. Anderson Cancer CenterNCT03873818Low dose with pembrolizumab in melanoma brain metastasesWritten as IpilimumabReport a problem
- A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCTActive, not recruitingPhase 1Dana-Farber Cancer InstituteNCT03912064Its dose with regulatory T-cell-depleted donor lymphocytesWritten as IpilimumabReport a problem
- Nivolumab With or Without Ipilimumab in Treating Patients With Persistent or Recurrent Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube CancerCompletedPhase 2National Cancer Institute (NCI)NCT02498600Added to nivolumab in ovarian cancerWritten as IpilimumabReport a problem
- T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian CancerTerminatedPhase 1/2Inge Marie SvaneNCT04611126Added in a second step to TIL therapyWritten as IpilimumabReport a problem
- Ipilimumab + Temozolomide in Metastatic MelanomaCompletedPhase 2M.D. Anderson Cancer CenterNCT01119508With temozolomide in metastatic melanomaWritten as IpilimumabReport a problem
- Neoadjuvant Ipilimumab in Prostate CancerCompletedPhase 2M.D. Anderson Cancer CenterNCT01194271With leuprolide before prostate surgeryWritten as IpilimumabReport a problem
- Ipilimumab + Androgen Depravation Therapy in Prostate CancerTerminatedPhase 2M.D. Anderson Cancer CenterNCT01377389Added to hormone therapy in prostate cancerWritten as IpilimumabReport a problem
- Study of Pembrolizumab Given With Ipilimumab or Placebo in Participants With Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (MK-3475-598/KEYNOTE-598)CompletedPhase 3Merck Sharp & Dohme LLCNCT03302234Added to pembrolizumab against placebo in lung cancerWritten as IpilimumabReport a problem
- Study of Nivolumab in Combination With Ipilimumab Versus Nivolumab in Combination With Ipilimumab Placebo in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NeckCompletedPhase 2Bristol-Myers SquibbNCT02823574Added to nivolumab against placebo in head and neck cancerWritten as IpilimumabReport a problem
- A Study of Multiple Immune and Disease Treatment Combinations in Participants With ER+HER2- Breast Cancer That Has SpreadCompletedPhase 1Bristol-Myers SquibbNCT04132817Added to nivolumab and nab-paclitaxel in one groupWritten as IpilimumabReport a problem
- An Investigational Immuno-therapy Study of Nivolumab Combined With Ipilimumab Compared to Nivolumab by Itself After Complete Surgical Removal of Stage IIIb/c/d or Stage IV MelanomaCompletedPhase 3Bristol-Myers SquibbNCT03068455Added to nivolumab after melanoma surgeryWritten as ipilimumabReport a problem
- Sipuleucel-T With Immediate vs. Delayed Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA-4) Blockade for Prostate CancerCompletedPhase 2University of California, San FranciscoNCT01804465Immediate or delayed after sipuleucel-T in prostate cancerWritten as IpilimumabReport a problem
Showing 20 of 41. See all 41 →
Tested in a combination · 412 — another drug in the study is under test too
- Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary TumorsRecruitingPhase 2National Cancer Institute (NCI)NCT03866382With nivolumab and cabozantinib in rare cancersWritten as IpilimumabReport a problem
- Testing an Immunotherapy Anti-cancer Drug, Nivolumab, for Advanced Cancers in Patients With Autoimmune Disorders, AIM-NIVORecruitingPhase 1National Cancer Institute (NCI)NCT03816345With nivolumab in people with autoimmune disease, some armsWritten as IpilimumabReport a problem
- Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IORecruitingPhase 2The Netherlands Cancer InstituteNCT03815890Added to nivolumab before breast surgeryWritten as IpilimumabReport a problem
- Neoadjuvant Nivolumab Plus Ipilimumab in Resectable NSCLC (GALAXY 3)RecruitingPhase 2The First Affiliated Hospital of Guangzhou Medical UniversityNCT06926790With nivolumab before lung cancer surgeryWritten as Nivolumab & IpilimumabReport a problem
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNot yet recruitingPhase 2Shanghai Zhongshan HospitalNCT07919717With nivolumab before repeat surgery for recurrent liver cancerWritten as IpilimumabReport a problem
- Evaluating the Safety of Shortened Infusion Times for dIfferent Oncological ImmunotherapieRecruitingPhase 4IsalaNCT06031233Shorter infusion times studiedWritten as IpilimumabReport a problem
- TACE or Ablation Combined With Sintilimab and Ipilimumab N01 as Neoadjuvant Therapy for Resectable Hepatocellular Carcinoma With Intermediate-High Recurrence RiskRecruitingPhase 2Sun Yat-sen UniversityNCT07487662Ipilimumab N01 with sintilimab before liver cancer surgeryReport a problem
- MELCHRONO: A Prospective Randomized Study Investigating Chrono-immunotherapy for Advanced Melanoma.RecruitingPhase 2Swiss Cancer InstituteNCT07574047Morning or afternoon infusions, one checkpoint optionReport a problem
- Cabozantinib Combined With Ipilimumab/Nivolumab and TACE in Patients With Hepatocellular CarcinomaRecruitingPhase 2University of California, IrvineNCT04472767With nivolumab, cabozantinib and TACE in liver cancerWritten as IpilimumabReport a problem
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaNot yet recruitingPhase 2Fudan UniversityNCT07893340Ipilimumab N01 with sintilimab and bevacizumab in mesotheliomaReport a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for High-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879586Ipilimumab N01 added to sintilimab and chemoradiotherapyWritten as Ipilimumab & SintilimabReport a problem
- Neoadjuvant Chemoradiotherapy Plus PD-1 Blockade ± CTLA-4 Blockade for Low/Intermediate-Risk Locally Advanced Rectal Cancer (pMMR/MSS): A National Multicenter, Prospective, Randomized Controlled TrialNot yet recruitingPhase 2/3Yao HongweiNCT07879599Ipilimumab N01 added to sintilimab and chemoradiotherapyWritten as Ipilimumab & SintilimabReport a problem
- A Phase II Study of Ipilimumab N01 Plus Sintilimab for MSI-H or dMMR Gastric and Gastroesophageal Junction CancerNot yet recruitingPhase 2Fudan UniversityNCT07878221Ipilimumab N01 with sintilimab in MSI gastric cancerReport a problem
- Immunotherapy in Combination With Prednisone and Sirolimus for Kidney Transplant Recipients With Unresectable or Metastatic Skin CancerRecruitingPhase 1/2National Cancer Institute (NCI)NCT05896839With nivolumab, sirolimus and prednisone in transplant recipientsWritten as IpilimumabReport a problem
- Bevacizumab and ICIs + hSRT in Symptomatic Melanoma Brain MetastasesRecruitingPhase 1/2Melanoma and Skin Cancer Trials LimitedNCT06163820With nivolumab, bevacizumab and radiotherapy for brain metastasesWritten as IpilimumabReport a problem
- Maintenance Niraparib Plus Ipilimumab in Patients With Metastatic Pancreatic Adenocarcinoma Whose Disease Has Not Progressed on Platinum-Based ChemotherapyRecruitingPhase 2Abramson Cancer Center at Penn MedicineNCT06747845With niraparib against FOLFIRI in pancreatic cancerWritten as IpilimumabReport a problem
- SBRT Followed by Ipilimumab N01, Sintilimab, Nab-Paclitaxel and Gemcitabine for Locally Advanced Pancreatic CancerRecruitingPhase 2Shandong Cancer Hospital and InstituteNCT07683221Ipilimumab N01 with sintilimab and chemotherapy after SBRTReport a problem
- A Study of Fianlimab, Cemiplimab, and Ipilimumab in People With MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT06594991With fianlimab and cemiplimab in melanomaWritten as IpilimumabReport a problem
- The Impact of Time-of-day-Dependent Administration of Nivolumab-Ipilimumab (ICI/ICI) Combination on Overall Survival in Adults With Advanced Kidney Cancer: A Pragmatic Multicenter, Randomized Controlled Trial.Not yet recruitingPhase 3Guliz OzgunNCT07338981With nivolumab, morning against afternoonWritten as Nivolumab & IpilimumabReport a problem
- Neoadjuvant Immune Checkpoint Inhibition and Novel IO Combinations in Early-stage Colon CancerRecruitingPhase 2The Netherlands Cancer InstituteNCT03026140With nivolumab before colon cancer surgeryWritten as IpilimumabReport a problem
Showing 20 of 412. See all 412 →
Beside an established treatment under test · 72 — an approved drug, surgery or radiation is what the study tests
Tested with Ipilimumab: Nivolumab 20 · Radiation 17 · Surgery or a procedure 16 · cabozantinib 4 · pembrolizumab 3 · Trabectedin 2 · A device 2 · PM 01183 2
- First-line Immunotherapy-based Standard of Care and Local Ablative Treatments for Oligometastatic Non-small Cell Lung Cancer Patients.RecruitingPhase 3Gustave Roussy, Cancer Campus, Grand ParisNCT06840782Usual immunotherapy; local ablative treatment is addedReport a problem
- Prophylactic Mesalamine to Prevent Colitis Following Treatment With Ipilimumab/Nivolumab (Ipi/Nivo)RecruitingPhase 2AHS Cancer Control AlbertaNCT05663775Usual treatment with nivolumab; mesalamine is addedReport a problem
- Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI TrialRecruitingPhase 2NRG OncologyNCT05327686In every armUsual immunotherapy in both arms; radiotherapy is addedWritten as IpilimumabReport a problem
- Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the LiverRecruitingNot applicableMassachusetts General HospitalNCT07364474Usual care with liver perfusion in one armReport a problem
- ONO-4538 Phase II Rollover Study (ONO-4538-98)RecruitingPhase 2Ono Pharmaceutical Co., Ltd.NCT04566380Continued in a nivolumab rollover studyWritten as IpilimumabReport a problem
- Concurrent Immunotherapy and Systemic Therapy With Stereotactic Body Radiation Therapy (SBRT) for Stage IV Cancers (COINSSS IV)RecruitingPhase 2Mark BernardNCT07770100In every armUsual immunotherapy; SBRT is addedWritten as IpilimumabReport a problem
- Anti-PD 1 Brain Collaboration + Radiotherapy Extension (ABC-X Study)RecruitingPhase 2Melanoma Institute AustraliaNCT03340129In every armBoth arms take it with nivolumab; radiosurgery is addedWritten as IpilimumabReport a problem
- Deferred Cytoreductive Nephrectomy in Synchronous Metastatic Renal Cell Carcinoma: The NORDIC-SUN-TrialRecruitingNot applicableNiels FristrupNCT03977571Usual induction with nivolumab; deferred surgery is studiedReport a problem
- OBSERVE: A Pilot Study Of Omission Of Brain Metastasis Stereotactic Radiosurgery Following Resection With CNS-Active Systemic TherapyRecruitingPhase 1M.D. Anderson Cancer CenterNCT07655583One option of brain-active therapy; skipping radiosurgery is studiedReport a problem
- Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT TrialRecruitingPhase 3NRG OncologyNCT07166406In every armUsual immunotherapy; radiotherapy is addedWritten as IpilimumabReport a problem
- A Phase I Study of Pazopanib in Combination With Trabectedin, Ipilimumab and Nivolumab (TraPIN) in Pediatric and Young Adult Patients With Recurrent Soft Tissue SarcomasRecruitingPhase 1M.D. Anderson Cancer CenterNCT07444619In every armPartner while pazopanib's dose is escalatedWritten as IpilimumabReport a problem
- A Study Evaluating The Combination of Immunotherapy With Radiotherapy in Non-Small Cell Lung CancerRecruitingPhase 2University of ChicagoNCT07603856One standard immunotherapy option; radiotherapy is addedReport a problem
- SSRI Antidepressant Fluoxetine Improving Immunotherapy Efficacy in Advanced Hepatobiliary Malignancy Patients With Depression and AnxietyRecruitingPhase 2First Affiliated Hospital of Wenzhou Medical UniversityNCT07174947One standard option; fluoxetine is addedReport a problem
- Axitinib and Nivolumab for the Treatment of Mucosal MelanomaRecruitingPhase 2Memorial Sloan Kettering Cancer CenterNCT05384496In every armNamed beside nivolumab; axitinib is what is addedWritten as Nivolumab and/or IpilimumabReport a problem
- Treatment of Cancer With Immune Checkpoint Inhibition Therapy Boosted by High Intensity Focused Ultrasound HistotripsyRecruitingPhase 1UMC UtrechtNCT06524570Usual treatment with nivolumab; histotripsy is addedReport a problem
- Immediate Versus Deferred Cytoreductive Nephrectomy With Ipilimumab/Nivolumab in mRCCNot yet recruitingNot applicableSeoul National University HospitalNCT07233668Both arms take it with nivolumab; surgery timing is studiedReport a problem
- Naltrexone and Propranolol Combined With ImmunotherapyRecruitingPhase 1Sarah WeissNCT05968690Usual treatment with nivolumab; propranolol and naltrexone are addedReport a problem
- Safe Stop Ipilimumab-nivolumab (IPI-NIVO) TrialRecruitingNot applicableErasmus Medical CenterNCT05652673Given before; early stopping of nivolumab is studiedReport a problem
- SAINT:Trabectedin, Ipilimumab and Nivolumab for Previously Treated Advanced Soft Tissue SarcomaRecruitingPhase 1/2Sarcoma Oncology Research Center, LLCNCT03138161In every armFixed partner while trabectedin's dose is escalatedWritten as IpilimumabReport a problem
- PHP in Combination With IPI1/NIVO3 Compared to IPI3/NIVO1 Only in Patients With Uveal Melanoma Liver MetastasesRecruitingPhase 3Vastra Gotaland RegionNCT06519266Both arms take it with nivolumab; liver perfusion is addedWritten as IPI1/NIVO3Report a problem
Showing 20 of 72. See all 72 →
Beside a new treatment under test · 229 — a new drug, cell therapy or vaccine is what the study tests
New treatments tested with Ipilimumab: Nivolumab 14 · cemiplimab 5 · tilsotolimod 4 · pepinemab 3 · clostridium butyricum miyairi 588 strain 3 · vopratelimab 3 · lirilumab 3 · pembrolizumab 3
- Study to Evaluate VT3989 in Patients With Metastatic Solid TumorsRecruitingPhase 1/2Vivace Therapeutics, IncNCT04665206Partner of new VT3989Written as Nivolumab & IpilimumabReport a problem
- A Multicenter Study Evaluating the Efficacy and Safety of Nivolumab and Ipilimumab in Combination With NP-101 Versus Placebo in Refractory Advanced and Metastatic Gastroenteropancreatic Neuroendocrine Carcinomas (GEP-NECs)Not yet recruitingPhase 2/3Novatek PharmaceuticalsNCT07935928In every armGiven with nivolumab in all arms; new NP-101 is tested against placeboReport a problem
- A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid TumorsRecruitingPhase 1Arcus Biosciences, Inc.NCT05536141Given with casdatifan and zimberelimab in two cohortsWritten as IpilimumabReport a problem
- Pan Tumor Rollover StudyRecruitingPhase 2Bristol-Myers SquibbNCT03899155Continued in a rollover study after earlier studiesWritten as IpilimumabReport a problem
- A 2-part Phase 1/2 Open-label Trial on ODM-212RecruitingPhase 1/2Orion Corporation, Orion PharmaNCT07563738Partner of new ODM-212 in one cohortReport a problem
- A DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Glutamine Antagonist DRP-104, Nivolumab, and Ipilimumab in Patients With Advanced Stage Fibrolamellar Carcinoma (FLC)RecruitingPhase 1Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsNCT07430202In every armPartner of new sirpiglenastat and a peptide vaccineWritten as IpilimumabReport a problem
- A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)RecruitingPhase 1/2Bristol-Myers SquibbNCT07291076Partner of new pumitamigWritten as IpilimumabReport a problem
- A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)RecruitingPhase 1/2Bristol-Myers SquibbNCT07293351Partner of new pumitamigWritten as IpilimumabReport a problem
- Symbiotic-GU-08: A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell CancerRecruitingPhase 1/2PfizerNCT07227415Partner of new PF-08634404Written as IpilimumabReport a problem
- Symbiotic-GI-13: A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.RecruitingPhase 1/2PfizerNCT07227012In every armPartner of new PF-08634404Written as IpilimumabReport a problem
- Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid TumorsRecruitingPhase 1ExelixisNCT05176483Partner of new zanzalintinibWritten as IpilimumabReport a problem
- A Phase 1b Study of HC-7366, an Agonist of ISR With Immunotherapy in Kidney Cancer (SHARK)RecruitingPhase 1M.D. Anderson Cancer CenterNCT07401875Partner of new HC-7366Written as ipilimumabReport a problem
- Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain MetastasisRecruitingPhase 1/2Neonc Technologies, Inc.NCT06047379Partner of new NEO212Written as IpilimumabReport a problem
- A Study of BMS-986504 With Standard-of-Care Therapy for People With Solid Tumor CancerRecruitingPhase 1Memorial Sloan Kettering Cancer CenterNCT07532902Partner of new navlimetostatWritten as IpilimumabReport a problem
- iSCIB1+ in Combination With Ipilimumab and Nivolumab as First-Line Treatment for Advanced Unresectable MelanomaNot yet recruitingPhase 3Scancell LtdNCT07815574In every armBoth arms take it with nivolumab; new iSCIB1+ is addedWritten as Nivolumab & IpilimumabReport a problem
- Combination Immunotherapy Treatment for Locally Advanced Unresectable or Metastatic, PD-L1 Negative (CPS<10), gBRCA Negative, Triple Negative Breast Cancer Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingPhase 1/2BreakBio CorpNCT07762703Partner of new BreakVaxWritten as Ipilimumab 2.5 mgReport a problem
- Combination Immunotherapy Treatment for Glioblastoma Including BreakVax ImmunoTreatment (Designed and Manufactured Per Patient), Chemotherapy and Anti PD-1 TherapyNot yet recruitingPhase 1/2BreakBio CorpNCT07762716In every armPartner of new BreakVaxWritten as Ipilimumab 2.5 mgReport a problem
- A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC)RecruitingPhase 1Bristol-Myers SquibbNCT07195682Partner of new BMS-986506Written as IpilimumabReport a problem
- Gut Microbiota Modulation for Immunotherapy Resensitization in Advanced Renal Cell CarcinomaRecruitingPhase 2Jinling Hospital, ChinaNCT07611825In every armPartner; gut microbiota modulation is studiedWritten as IpilimumabReport a problem
- Inulin Gel in Combination With Ipilimumab and Nivolumab for the Treatment of Metastatic or Locally Advanced Kidney Cell Cancer, ICON TrialRecruitingPhase 1/2University of Michigan Rogel Cancer CenterNCT06866262In every armBoth arms take it with nivolumab; inulin gel is addedWritten as IpilimumabReport a problem
Showing 20 of 229. See all 229 →
Beside supportive care · 11 — a supportive treatment or test is studied
- Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV MelanomaRecruitingPhase 2NYU Langone HealthNCT05428007In every armPartner; sarilumab is added to prevent side effectsWritten as Ipilimumab InjectionReport a problem
- Adding Anakinra and Tocilizumab to Nivolumab and Ipilimumab for the Treatment of Melanoma Patients 50 Years of Age or OlderNot yet recruitingPhase 1University of Southern CaliforniaNCT07838974In every armPartner; anakinra and tocilizumab are addedWritten as IpilimumabReport a problem
- Physical Activity Directly Before Immunotherapy (Nivolumab and Ipilimumab) in MelanomaRecruitingNot applicableUniversitätsklinikum Hamburg-EppendorfNCT07564570Usual treatment with nivolumab; exercise before it is studiedReport a problem
- Study to Evaluate Impact® as Support to Anti PD1 or Anti PD1 Based Regimen Treatment in Patients With Inoperable Locally Advanced or Metastatic MelanomaRecruitingNot applicableFondazione Melanoma OnlusNCT06880198Usual treatment; a nutrition supplement is addedReport a problem
- Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial CarcinomaTerminatedPhase 2M.D. Anderson Cancer CenterNCT04940299In every armPartner; tocilizumab is added to prevent side effectsWritten as IpilimumabReport a problem
- TNF-Inhibitor as Immune Checkpoint Inhibitor for Advanced MELanomaCompletedPhase 1Institut Claudius RegaudNCT03293784Partner; anti-TNF drugs are addedReport a problem
- Exercise to Boost Response to Checkpoint Blockade ImmunotherapyActive, not recruitingEarly Phase 1H. Lee Moffitt Cancer Center and Research InstituteNCT05358938One checkpoint drug given; exercise is studiedReport a problem
- Impact of a Prebiotic Food-enriched Diet (PreFED) in Combination With Ipilimumab/Nivolumab Combination Immune Checkpoint Blockade (ICB) in ICB-refractory Melanoma PatientsActive, not recruitingPhase 2M.D. Anderson Cancer CenterNCT06250335In every armPartner with nivolumab; a prebiotic diet is addedWritten as IpilimumabReport a problem
- A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV MelanomaActive, not recruitingPhase 2NYU Langone HealthNCT03999749In every armPartner; tocilizumab is added to prevent side effectsWritten as IpilimumabReport a problem
- A Pilot Study Evaluating a Ketogenic Diet Concomitant to Nivolumab and Ipilimumab in Patients With Metastatic Renal Cell CarcinomaTerminatedNot applicableGustave Roussy, Cancer Campus, Grand ParisNCT05119010Usual treatment with nivolumab; a ketogenic diet is studiedReport a problem
- Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of Investigational Treatments in Combination With Standard of Care Immune Checkpoint Inhibitors in Participants With Advanced MelanomaTerminatedPhase 1Millennium Pharmaceuticals, Inc.NCT02723006Partner; vedolizumab is added to prevent colitisWritten as ipilimumabReport a problem
One option of several · 3 — a test or a strategy chooses among drugs
- Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringRecruitingPhase 2H. Lee Moffitt Cancer Center and Research InstituteNCT07930182In every armAdded when ctDNA testing calls for more treatmentWritten as IpilimumabReport a problem
- Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialTerminatedPhase 1OHSU Knight Cancer InstituteNCT03878524In every armOne of many drugs chosen from tumour testingWritten as IpilimumabReport a problem
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyActive, not recruitingPhase 2Fondazione per la Medicina PersonalizzataNCT04591431One of many drugs in tailored therapyWritten as IpilimumabReport a problem
Given beside what is tested · 1 — usual care or a partner of the new treatment
As the comparator · 27 — what is tested is compared with Ipilimumab
- A Randomized Trial of Fianlimab and Cemiplimab +/- Ipilimumab or Ipilimumab Plus Nivolumab in First-line Advanced Renal Cell Carcinoma (RCC)RecruitingPhase 2Brian RiniNCT07188896The comparator, and added in one arm to new fianlimabWritten as IpilimumabReport a problem
- SUPRAME-ACTengine® IMA203 vs. Investigator's Choice of Treatment in Previously Treated, Unresectable or Metastatic Cutaneous MelanomaRecruitingPhase 3Immatics US, Inc.NCT06743126One of the comparators for new IMA203Written as ipilimumabReport a problem
- A Clinical Study of Ivonescimab in Combination With Cadonilimab or Ipilimumab for Advanced Renal CancerNot yet recruitingPhase 2Summit TherapeuticsNCT07877194The comparator, and partner of new ivonescimab in one armWritten as Ivonescimab combined with IpilimumabReport a problem
- A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory MelanomaRecruitingPhase 2/3Linnaeus Therapeutics, Inc.NCT06624644One of the comparators for new LNS8801Report a problem
- A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal MelanomaRecruitingPhase 2/3Replimune, Inc.NCT06581406The comparator for new RP2 virusWritten as IpilimumabReport a problem
- Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular CarcinomaRecruitingPhase 1Shanghai Henlius BiotechNCT07176650The reference for biosimilar HLX13Written as YervoyReport a problem
- A Study to Compare the Efficacy, Safety, Immunogenicity, and Pharmacokinetic Profile of HLX13 with YERVOY As a First-Line Treatment for Patients with Unresectable Hepatocellular CarcinomaNot yet recruitingPhase 3Shanghai Henlius BiotechNCT06841185The reference for biosimilar HLX13Written as US-sourced YERVOY®Report a problem
- A Study to Compare the PK , Safety, Tolerability, and Immunogenicity of HLX13 With YERVOY in Male SubjectsRecruitingPhase 1Shanghai Henlius BiotechNCT06159101The reference for biosimilar HLX13Written as EU-sourced ipilimumab groupReport a problem
- Physician/Patient Choice of Either High-Dose Recombinant Interferon Alfa-2B or Ipilimumab, Versus Pembrolizumab in Treating Patients With Stage III-IV High Risk Melanoma That Has Been Removed by SurgeryActive, not recruitingPhase 3National Cancer Institute (NCI)NCT02506153The comparator for pembrolizumab after melanoma surgeryWritten as IpilimumabReport a problem
- Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal MelanomaCompletedPhase 2Immunocore LtdNCT03070392One of the comparators for new tebentafuspWritten as IpilimumabReport a problem
- MEDI5752 in Combination With Carboplatin Plus Pemetrexed in Unresectable Pleural MesotheliomaActive, not recruitingPhase 3AstraZenecaNCT06097728Part of the comparator for new volrustomigWritten as IpilimumabReport a problem
- DuRvalumab With chEmotherapy as First Line treAtment in Advanced Pleural MesotheliomaCompletedPhase 3PrECOG, LLC.NCT04334759Part of a comparator arm for durvalumabReport a problem
- Comparative Pharmacokinetics of SHR-8068 and Ipilimumab in Healthy Chinese MenCompletedPhase 1The Affiliated Hospital of Qingdao UniversityNCT07852325The reference for SHR-8068Written as IpilimumabReport a problem
- A Study to Investigate the Efficacy and Safety of Volrustomig ± Casdatifan vs Nivolumab + Ipilimumab as 1L Treatment for Advanced ccRCCActive, not recruitingPhase 1AstraZenecaNCT07000149The comparator for new volrustomigReport a problem
- A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced MelanomaTerminatedPhase 2PfizerNCT05926960The comparator for encorafenib, binimetinib and pembrolizumabWritten as ipilimumabReport a problem
- IDE196 (Darovasertib) in Combination With Crizotinib as First-line Therapy in Metastatic Uveal MelanomaActive, not recruitingPhase 2/3IDEAYA BiosciencesNCT05987332One of the comparators for new darovasertibWritten as IpilimumabReport a problem
- Advanced Renal Cell Cancer Combination ImmunoThErapy Clinical TrialSuspendedPhase 2Michael B. Atkins, MDNCT05928806The comparator for new botensilimab and balstilimabWritten as IpilimumabReport a problem
- A Study of BMS-986249 Alone and in Combination With Nivolumab in Advanced Solid TumorsCompletedPhase 1/2Bristol-Myers SquibbNCT03369223The comparator for new BMS-986249Written as IpilimumabReport a problem
- A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Patients With Melanoma (Morpheus-Melanoma)CompletedPhase 1/2Hoffmann-La RocheNCT05116202The comparator for new tobemstomig combinationsWritten as IpilimumabReport a problem
- Phase 3 Study of Nivolumab or Nivolumab Plus Ipilimumab Versus Ipilimumab Alone in Previously Untreated Advanced Melanoma (CheckMate 067)CompletedPhase 3Bristol-Myers SquibbNCT01844505On the US labelThe comparator, and partner of new nivolumabWritten as IpilimumabReport a problem
Showing 20 of 27. See all 27 →
Observed · 99 — patients on it are followed, or it is given outside a trial
- Development and Analysis of a Stool Bank for Cancer PatientsEnrolling by invitationPersephone BiosciencesNCT04291755Stool samples in people treated with checkpoint drugsReport a problem
- JOint Use of Database to Identify Risk Factors of CARDio-vascular Toxicity Induced by Immune Checkpoint InhibitorsRecruitingGroupe Hospitalier Pitie-SalpetriereNCT04294771Heart side effects of checkpoint drugs in a databaseReport a problem
- Biomarker and Mechanism Study of Systemic Therapy in Unresectable HCCNot yet recruitingShanghai Zhongshan HospitalNCT07786792One of the liver cancer regimens observedReport a problem
- Digital Remote Monitoring of Immune Checkpoint Inhibitor Therapy Induced Toxicity Using the Vigilant AppRecruitingMayo ClinicNCT06675643Side effects tracked in an appReport a problem
- Impact of Physical Activity on Immunotherapy-induced Toxicities in Melanoma ManagementRecruitingUniversity Hospital, MontpellierNCT06627595Physical activity and side effects of immunotherapyReport a problem
- First-Line Nivolumab Plus Ipilimumab in Unresectable Hepatocellular Carcinoma (J-PROMISE)RecruitingBristol-Myers SquibbNCT07679061With nivolumab, real-world liver cancer in JapanWritten as Nivolumab plus ipilimumabReport a problem
- Real-World Comparison of Chemo-Immunotherapy Regimens in Metastatic NSCLC With PD-L1 <50% (ALCG-01)RecruitingGazi UniversityNCT07394062With nivolumab and chemotherapy, real-world comparisonWritten as Ipilimumab (1mg/kg)Report a problem
- TDM for Optimized Outcome in Patients With mRCC.RecruitingNiels FristrupNCT04659343Drug levels measured during treatmentReport a problem
- Different First-line Immunotherapy for Advancer Hepatocellular Carcinoma: A Prospective Observational Study on Efficacy and Immune MicroenvironmentRecruitingFudan UniversityNCT07147101With nivolumab, one of several liver cancer cohortsWritten as IpilimumabReport a problem
- Montreal Immune-Related Adverse Events (MIRAE) StudyRecruitingSir Mortimer B. Davis - Jewish General HospitalNCT05139706Side effects of checkpoint drugs observedReport a problem
- International Multicentric Study ARON-1RecruitingHospital of MacerataNCT05287464With nivolumab, one of several kidney cancer regimens observedReport a problem
- First-line Therapy With Nivolumab Plus Ipilimumab in Combination With Chemotherapy for Metatastatic NSCLC (NICReWo Trial)RecruitingFondazione IRCCS Policlinico San Matteo di PaviaNCT07190677With nivolumab and chemotherapy, real-world lung cancer in ItalyReport a problem
- Patient Reported Outcome Measurements (PROMs) Impact on Clinical Outcome in firsT Line settIng Non- Small-Cell Lung Cancer (NSCLC) According to Chemo- Immunotherapy reGimenRecruitingIRCCS San RaffaeleNCT07061379With nivolumab and chemotherapy, patient-reported outcomesReport a problem
- Observational Study of Patients with Advanced Melanoma (skin Cancer) to Assess If IOpener®-melanoma Test Can Predict Response to Immunotherapy.RecruitingPamgene International B.V.NCT06784778With nivolumab, a response test in melanomaReport a problem
- Impact of Telemonitoring for the Management of Side Effects in Patients with Melanoma, Lung or Renal Cancer, Treated with Immunotherapy Combination of Nivolumab and Ipilimumab or Adjuvant Nivolumab MonotherapyRecruitingNot applicableHospices Civils de LyonNCT04605146Telemonitoring during treatment with itReport a problem
- Immunological Functionnal Test Validation to Predict Melanoma Metastatic Patient Response to Checkpoint InhibitorsRecruitingNot applicableCentre Hospitalier Universitaire de NiceNCT05649683Immune test in people treated with itReport a problem
- Microbiome Immunotherapy Toxicity and Response EvaluationRecruitingCCTU- Cancer ThemeNCT04107168Observed with other checkpoint drugs, gut microbiomeWritten as IpilimumabReport a problem
- TNF in Melanoma Patients Treated With ImmunotherapyCompletedNot applicableInstitut Claudius RegaudNCT03348891Blood samples in people treated with itReport a problem
- Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung Cancer Treated With First-line Nivolumab + Ipilimumab + 2 Cycles of ChemotherapyCompletedBristol-Myers SquibbNCT07024862With nivolumab, long-term lung cancer outcomesWritten as nivolumab + ipilimumabReport a problem
- Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Cancer and Programmed Death-1 (Pd-L1) <1%CompletedBristol-Myers SquibbNCT07215962With nivolumab, long-term lung cancer safetyWritten as Nivolumab + ipilimumabReport a problem
Showing 20 of 99. See all 99 →
As a tool · 6 — an imaging tracer or a test of drug response
- Implantable Microdevices for in Situ Evaluation of Drug Responses in Lung CancerRecruitingEarly Phase 1Oliver JonasNCT07892300A microdose in an implanted device to test responseReport a problem
- Implantable Microdevice In Primary Brain TumorsRecruitingEarly Phase 1Oliver JonasNCT04135807A microdose in an implanted device to test responseReport a problem
- Pilot Study of an Implantable Microdevice for Evaluating Drug Responses in Situ in Prostate CancerEnrolling by invitationPhase 1Brigham and Women's HospitalNCT04399876A microdose in an implanted device to test responseReport a problem
- Drug Screening Using Novel IMD in Renal Cell CarcinomaRecruitingPhase 1Oliver JonasNCT05700461A microdose in an implanted device to test responseReport a problem
- Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue SarcomaCompletedPhase 1Presage BiosciencesNCT03056599A microdose injected to test tumour responseReport a problem
- Uptake and Biodistribution of 89Zirconium-labeled Ipilimumab in Ipilimumab Treated Patients With Metastatic MelanomaStatus unknownPhase 2Amsterdam UMC, location VUmcNCT03313323Labelled with zirconium as a tracerReport a problem
What changed recently
From the registry's own updates since Oct 20, 2026.
Started recruiting1
Results posted1
- Study of Nivolumab and Ipilimumab in Children and Young Adults With INI1-Negative CancersOct 20, 2026NCT04416568
Newly registered4
- First-Line Nivolumab Plus Ipilimumab or Cabozantinib Followed by Second-Line Lenvatinib Plus Everolimus in Metastatic TFE-Rearranged Renal Cell CarcinomaNov 18, 2026NCT07947277
- A Prospective Cohort Study of PD-1 Monoclonal Antibody Combined With Ipilimumab N01 and Chemotherapy in Perioperative Treatment of Resectable Non-small Cell Lung CancerNov 5, 2026NCT07917767
- NIVO+IPI Neoadjuvant Therapy for Recurrent Resectable HCCNov 5, 2026NCT07919717
- First-line Treatment With Dual Immunotherapy Combined With Anti-angiogenesis for Unresectable Advanced Malignant Peritoneal MesotheliomaOct 23, 2026NCT07893340
Codes
What other systems call Ipilimumab · ClinicalTrials.gg INT006640
- MeSH (NLM) D000074324IpilimumabConfirmed ClinicalTrials.gov, Wikidata
- UNII (FDA) 6T8C155666IPILIMUMABConfirmed FDA, Wikidata
- RxNorm 1094833Confirmed FDA, Wikidata
- Wikidata Q2459042ipilimumabConfirmed FDA, Wikidata
- NCI Thesaurus C2654IpilimumabOne source FDA
- DrugBank DB06186One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D000074324 | Ipilimumab | Confirmed ClinicalTrials.gov, Wikidata |
| UNII (FDA) | 6T8C155666 | IPILIMUMAB | Confirmed FDA, Wikidata |
| RxNorm | 1094833 | — | Confirmed FDA, Wikidata |
| Wikidata | Q2459042 | ipilimumab | Confirmed FDA, Wikidata |
| NCI Thesaurus | C2654 | Ipilimumab | One source FDA |
| DrugBank | DB06186 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.